|
US3227725A
(en)
|
1962-04-17 |
1966-01-04 |
Union Carbide Corp |
Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
TW201311B
(https=)
|
1991-06-17 |
1993-03-01 |
Hoffmann La Roche |
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
CA2143246C
(en)
|
1994-03-16 |
2000-08-22 |
Thierry Godel |
Imidazodiazepines
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
DK0999825T3
(da)
|
1997-07-29 |
2004-02-09 |
Alcon Lab Inc |
Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
|
|
US6110973A
(en)
|
1998-01-29 |
2000-08-29 |
Sepracor |
Methods for treating obesity and weight gain using optically pure (-)-bupropion
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
ES2747357T3
(es)
|
2001-03-14 |
2020-03-10 |
Dako Denmark As |
Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
|
|
EP2388590A1
(en)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, a receptor for B7-4, and uses thereof
|
|
AU2002258941A1
(en)
|
2001-04-20 |
2002-11-05 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
GB0204159D0
(en)
|
2002-02-22 |
2002-04-10 |
British Biotech Pharm |
Metalloproteinase inhibitors
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
CA2534484A1
(en)
|
2003-08-07 |
2005-02-17 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes and methods for making and using same
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
US7569578B2
(en)
|
2003-12-05 |
2009-08-04 |
Bristol-Meyers Squibb Company |
Heterocyclic anti-migraine agents
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
|
JP5065908B2
(ja)
|
2004-12-24 |
2012-11-07 |
プロシディオン・リミテッド |
Ｇタンパク質結合受容体作動薬
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
EP1888512A2
(en)
|
2005-06-06 |
2008-02-20 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US20090042926A1
(en)
|
2005-12-20 |
2009-02-12 |
Jason Imbriglio |
Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
|
|
US8748627B2
(en)
|
2006-02-15 |
2014-06-10 |
Abbvie Inc. |
Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
|
|
EP2044061A2
(en)
|
2006-07-20 |
2009-04-08 |
Mehmet Kahraman |
Benzothiophene inhibitors of rho kinase
|
|
NZ575795A
(en)
|
2006-09-25 |
2012-03-30 |
Ptc Therapeutics Inc |
Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
WO2009006555A2
(en)
|
2007-07-02 |
2009-01-08 |
Yu, Ming |
Methods, composition, targets for combinational cancer treatments
|
|
US7868001B2
(en)
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
|
CA2714700C
(en)
|
2008-02-22 |
2013-07-30 |
Irm Llc |
Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
|
|
US20110275673A1
(en)
|
2008-09-19 |
2011-11-10 |
Yibin Xiang |
Inhibitors of sphingosine kinase 1
|
|
EP2349266A4
(en)
|
2008-10-30 |
2012-06-06 |
Elixir Pharmaceuticals Inc |
Sulphonamide-containing compounds and their uses
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
|
WO2011137587A1
(en)
|
2010-05-06 |
2011-11-10 |
Hutchison Medipharma Limited |
Cytokine inhibitors
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
NZ607337A
(en)
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
WO2012129564A2
(en)
|
2011-03-24 |
2012-09-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Proteasome chymotrypsin-like inhibition using pi-1833 analogs
|
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
KR20140069235A
(ko)
|
2011-09-27 |
2014-06-09 |
노파르티스 아게 |
돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
AU2013239366A1
(en)
|
2012-03-29 |
2014-10-16 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the BC loop of human PD1
|
|
CA2886433C
(en)
|
2012-10-04 |
2022-01-04 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
EP2906684B8
(en)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
CA2896244C
(en)
|
2013-01-09 |
2017-07-04 |
Gilead Sciences, Inc. |
5-membered heteroaryls and their use as antiviral agents
|
|
EP2970240B1
(en)
|
2013-03-14 |
2018-01-10 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
WO2014147586A1
(en)
|
2013-03-22 |
2014-09-25 |
Novartis Ag |
1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
|
|
CA2916681A1
(en)
|
2013-07-16 |
2015-01-22 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
CA2920113A1
(en)
|
2013-08-20 |
2015-02-26 |
Merck Sharp & Dohme Corp. |
Treating cancer with a combination of a pd-1 antagonist and dinaciclib
|
|
HRP20181052T1
(hr)
|
2013-09-06 |
2018-09-07 |
Aurigene Discovery Technologies Limited |
Derivati 1,2,4-oksadiazola kao imunomodulatori
|
|
SI3041828T1
(sl)
|
2013-09-06 |
2018-10-30 |
Aurigene Discovery Technologies Limited |
1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
KR20160093012A
(ko)
|
2013-11-05 |
2016-08-05 |
코그네이트 바이오서비시즈, 인코포레이티드 |
암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
|
|
GB2516515B8
(en)
|
2013-12-04 |
2016-10-05 |
Intelligent Growth Solutions Ltd |
Automated arrangement to grow plants under lighting in a vertical tower
|
|
WO2015088847A1
(en)
|
2013-12-11 |
2015-06-18 |
Glaxosmithkline Llc |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
|
RS63295B1
(sr)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Anti-vista antitela i fragmenti
|
|
JP2016021697A
(ja)
|
2014-07-15 |
2016-02-04 |
株式会社日立製作所 |
通信システム、通信装置、及び、制御装置
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
|
WO2016073470A1
(en)
|
2014-11-04 |
2016-05-12 |
The University Of Kansas |
Lkb1-ampk activators for therapeutic use in polycystic kidney disease
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
BR112017019306A2
(pt)
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores
|
|
NZ734650A
(en)
*
|
2015-03-10 |
2023-07-28 |
Aurigene Oncology Ltd |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
EP3267985A4
(en)
*
|
2015-03-10 |
2018-07-25 |
Aurigene Discovery Technologies Limited |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
WO2018047143A1
(en)
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Vista signaling pathway inhibitory compounds useful as immunomodulators
|
|
WO2018051254A1
(en)
*
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
|
MY205585A
(en)
|
2016-10-20 |
2024-10-28 |
Aurigene Oncology Ltd |
Dual inhibitors of vista and pd-1 pathways
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
IL273896B2
(en)
|
2017-10-11 |
2025-08-01 |
Aurigene Oncology Ltd |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
|
AU2018360386B2
(en)
|
2017-11-03 |
2023-11-09 |
Aurigene Oncology Limited |
Dual inhibitors of TIM-3 and PD-1 pathways
|
|
CN111386128A
(zh)
|
2017-11-06 |
2020-07-07 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的联合疗法
|